Stew Kroll

3.4k citations

31 papers · 1.6k indexed · h-index 16

Impact in

Ophthalmology top 2%
- Ocular Oncology and Treatments
Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism

Papers in

Cancer Research 9
- Cancer, Hypoxia, and Metabolism 8
Ophthalmology 5
- Ocular Oncology and Treatments 5

Co-authors: Devron H. Char George F. Tidmarsh T. Andrew Lister John P. Leonard Robert Stagg Mansoor N. Saleh Louis Fehrenbacher Susan J. Knox
Journals: Journal of Clinical Oncology (15 papers)Ophthalmology (4 papers)Clinical Cancer Research (1 paper)Journal of Cardiothoracic and Vascular Anesthesia (1 paper)International Journal of Radiation Oncology*Biology*Physics (1 paper)
Partner nations: United States Australia Germany

In The Last Decade

Stew Kroll

31 papers receiving 1.6k citations

Peers

Countries citing papers authored by Stew Kroll

Since Specialization

Citations

This map shows the geographic impact of Stew Kroll's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stew Kroll with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stew Kroll more than expected).

Fields of papers citing papers by Stew Kroll

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stew Kroll. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stew Kroll. The network helps show where Stew Kroll may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Stew Kroll, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stew Kroll Line = papers co-authored together Stew Kroll links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Leukocyte immunoglobulin-like receptor (LILRB2)-targeted JTX-8064 plus the anti-PD1 inhibitor JTX-4014 (pimivalimab) in immune-checkpoint inhibitor (ICl) pretreated patients (pts) with advanced or metastatic renal cell cancer (mRCC): Results from the multi-stage phase 1-2 INNATE trial. Journal of Clinical Oncology ·Primo N. Lara, Stew Kroll, 黄剑青, Deanna Teoh, T. Vincent, Deepak Kilari, Clara Hwang, Randy F. Sweis, Kiran Yalamanchili, Julio A. Peguero, Tianhong Li, Mamta Parikh	2024	1
2	Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial Critical Care ·Patrick M. Wieruszewski, Rinaldo Bellomo, Laurence W. Busse, Kealy R. Ham, Alexander Zarbock, Ashish K. Khanna, Adam M. Deane, Marlies Ostermann, Richard G. Wunderink, David W. Boldt, Stew Kroll, Chuck Greenfeld, Marzia Trillo, Jonathan H. Chow, (unknown)	2023	21
3	Treatment With Angiotensin II Is Associated With Rapid Blood Pressure Response and Vasopressor Sparing in Patients With Vasoplegia After Cardiac Surgery: A Post-Hoc Analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) Study Journal of Cardiothoracic and Vascular Anesthesia ·Orhan Akyüz, Ashish K. Khanna, V. Seenu Reddy, Bruce Friedman, Jamel Ortoleva, Adam S. Evans, Rakshit Panwar, Stew Kroll, Chuck Greenfeld, Subhasis Chatterjee	2020	55
4	Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II Critical Care Medicine ·James A. Tumlin, Raghavan Murugan, Adam M. Deane, Marlies Ostermann, Laurence W. Busse, Kealy R. Ham, Kianoush Kashani, Harold M. Szerlip, John R. Prowle, Azra Bihorac, Kevin W. Finkel, Alexander Zarbock, Lui G. Forni, S. Lynch, Mijail Vidal, Stew Kroll, Lakhmir S. Chawla, George F. Tidmarsh, Rinaldo Bellomo	2018	193
5	Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) data Journal of Critical Care ·赵福江, Ashish K. Khanna, Stew Kroll, Connor McNamara, Damian Handisides, Laurence W. Busse	2018	10
6	A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS). Journal of Clinical Oncology ·Danny Rischin, Michael Boyer, Christina Brzezniak, A. Dimitrios Colevas, Robert C. Doebele, Jill Gilbert, Barbara J. Gitlitz, Saad A. Khan, Ranee Mehra, Tanguy Y. Seiwert, Stew Kroll, Tillman Pearce, Stephen V. Liu	2016	3
7	Phase 2 study of tarloxotinib bromide (TRLX) in patients (pts) with EGFR-Mutant, T790M-Negative NSCLC progressing on an EGFR TKI. Journal of Clinical Oncology ·Stephen V. Liu, Charu Aggarwal, Christina Brzezniak, Robert C. Doebele, David E. Gerber, Barbara J. Gitlitz, Leora Horn, Benjamin Solomon, Maysa M. N. Taha, Liza C. Villaruz, Howard West, Stew Kroll, Tillman Pearce, D. Ross Camidge	2016	10
8	Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma Journal of Clinical Oncology ·Sant P. Chawla, Lee D. Cranmer, Brian A. Van Tine, Damon R. Reed, Scott H. Okuno, James E. Butrynski, Douglas R. Adkins, Andrew Hendifar, Stew Kroll, Kristen N. Ganjoo	2014	122
9	Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM). Journal of Clinical Oncology ·Jacob P. Laubach, Noopur Raje, Philippe Armand, Robert Schlossman, Jacalyn Rosenblatt, Jeffrey Matous, 孝之石曽根, Michael G. Martin, Craig H. Reynolds, Kenneth H. Shain, Monserrat González Monroy, Laura Stampleman, Pavla Třeštíková, Stacey Chuma, A. Kourkoumeli-Charalampidi, Damian Handisides, Stew Kroll, Kenneth C. Anderson, Paul G. Richardson, Irene M. Ghobrial	2014	1
10	Phase 1/2 study of investigational hypoxia-targeted drug, TH-302, and bevacizumab (bev) in recurrent glioblastoma (GBM) following bev failure. Journal of Clinical Oncology ·Andrew Brenner, Jessica D. Sun, John Floyd, Charles P. Hart, Clarence Eng, Stew Kroll, Lisa Fichtel, Aleksandra Gruslova, Alessia Lodi, Stefano Tiziani	2014	1
11	Randomized phase III, multicenter, open-label study comparing TH-302 in combination with doxorubicin versus doxorubicin alone in subjects with locally advanced unresectable or metastatic soft tissue sarcoma. Journal of Clinical Oncology ·Sant P. Chawla, Denise K. Reinke, 桂德超, Stew Kroll, William D. Tap	2012	2
12	Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies Clinical Cancer Research ·Glen J. Weiss, Jeffrey R. Infante, E. Gabriela Chiorean, Mitesh J. Borad, Johanna C. Bendell, Julian R. Molina, Raoul Tibes, Ramesh K. Ramanathan, Li-Yao Cheng, Suzanne F. Jones, Mario E. Lacouture, Virginia K. Langmuir, Е Ю Шипиевская, Stew Kroll, Howard A. Burris	2011	122
13	A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Oncology ·Kristen N. Ganjoo, Lee D. Cranmer, James E. Butrynski, Daniel A. Rushing, Douglas Adkins, Scott H. Okuno, Gustavo Lorente, Stew Kroll, Virginia K. Langmuir, Sant P. Chawla	2011	65
14	Resolution of Cullen’s sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302 SHILAP Revista de lepidopterología ·Glen J. Weiss, Li-Yao Cheng, Germana Ferrari, Stew Kroll	2011	4
15	Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas Journal of Clinical Oncology ·Mark Kaminski, Andrew D. Zelenetz, Oliver W. Press, Mansoor N. Saleh, John P. Leonard, Louis Fehrenbacher, T. Andrew Lister, Robert Stagg, George F. Tidmarsh, Stew Kroll, Richard L. Wahl, Susan J. Knox, Julie M. Vose	2001	442
16	A comparison of cause-specific melanoma mortality and all-cause mortality in survival analyses after radiation treatment for uveal melanoma Ophthalmology ·Stew Kroll, Devron H. Char, Jeanne M. Quivey, Joseph R. Castro	1998	51
17	Metastatic Risk for Distinct Patterns of Postirradiation Local Recurrence of Posterior Uveal Melanoma Ophthalmology ·J. William Harbour, Devron H. Char, Stew Kroll, Jeanne M. Quivey, Joseph R. Castro	1997	63
18	Prognostic factors in adult soft-tissue sarcomas of the head and neck International Journal of Radiation OncologyBiologyPhysics ·Quynh‐Thu Le, Karen K. Fu, Stew Kroll, Cuadrado Velastegui, Vincent Massullo, Linda D. Ferrell, Michael J. Kaplan, Theodore L. Phillips	1997	83
19	Iris Melanomas Ophthalmology ·Devron H. Char, Joanna Crawford, Stew Kroll	1996	17
20	p53 Gene and Cell Cycling in Uveal Melanoma American Journal of Ophthalmology ·規実生中里, Siavash Ghazvini, Devron H. Char, Stew Kroll, Yanan Li	1996	34

About Stew Kroll

Stew Kroll is a scholar working on Cancer Research, Ophthalmology, Oncology, Genetics and Hematology, having authored 31 papers that have together received 1.6k indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (8 papers), Ocular Oncology and Treatments (5 papers), Lung Cancer Treatments and Mutations (5 papers), Advanced Breast Cancer Therapies (4 papers), Multiple Myeloma Research and Treatments (4 papers), Cancer Treatment and Pharmacology (4 papers), Sarcoma Diagnosis and Treatment (4 papers) and Glioma Diagnosis and Treatment (3 papers). The work is most often cited by research in Ophthalmology (233 citations), Cancer Research (371 citations), Oncology (515 citations), Pathology and Forensic Medicine (335 citations) and Radiology, Nuclear Medicine and Imaging (398 citations). Stew Kroll has collaborated with scholars based in United States, Australia and Germany. Frequent co-authors include Devron H. Char, George F. Tidmarsh, T. Andrew Lister, John P. Leonard, Robert Stagg, Mansoor N. Saleh, Louis Fehrenbacher, Susan J. Knox, Andrew D. Zelenetz and Richard L. Wahl. Their work appears in journals such as Journal of Clinical Oncology, Ophthalmology, Clinical Cancer Research, Journal of Cardiothoracic and Vascular Anesthesia and International Journal of Radiation Oncology*Biology*Physics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact